TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05715372

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean diet
Description: 12-week structured program for Mediterranean diet.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean diet
Description: 12-week structured program for Mediterranean diet.
Study: NCT03887221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Safinamide 100mg
Description: Safinamide 100mg film-coated tablets will be administered to subjects in Cohort 2. The subjects will receive the tablets orally in the morning, at 8:00±1hour, under fasting conditions, with 240 mL (total volume) of still mineral water. A mouth-and-hand check will be performed immediately after dosing to ensure treatment compliance.
Study: NCT05715372

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: AHA walking program
Description: 12-week structured AHA walking program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: AHA walking program
Description: 12-week structured AHA walking program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-based stress reduction
Description: 8-week structured mindfulness-based stress reduction (Cabot).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-based stress reduction
Description: 8-week structured mindfulness-based stress reduction (Cabot).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Unstructured Mediterranean diet
Description: Unstructured 12-week program with basic outline for Mediterranean diet.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Unstructured Mediterranean diet
Description: Unstructured 12-week program with basic outline for Mediterranean diet.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Unstructured walking program
Description: Unstructured 12-week walking program.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Unstructured walking program
Description: Unstructured 12-week walking program.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Unstructured stress reduction
Description: Unstructured program using mobile application for stress reduction.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Unstructured stress reduction
Description: Unstructured program using mobile application for stress reduction.
Study: NCT06342973

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xenograft and allograft
Description: For the guided bone augmentation procedure, a crestal incision with one or two vertical incision will be made and a full thickness mucoperiosteal flap will be elevated. Decortication will be performed and the patient will receive grafting with DFDBA with a buccal overlay of xenograft. A bi-layered native collagen membrane will be used and fixed with tacks or sutures. Periosteal incisions will be made to get tension free primary closure. The flap will be closed with sutures. Patients will be prescribed antibiotics, analgesics and mouth rinses as appropriate.
Study: NCT04859816

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metabolic test
Description: Iv and oral administration of stable isotope tracers during fasting and a high-fat liquid mixed meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metabolic test
Description: Iv and oral administration of stable isotope tracers during fasting and a high-fat liquid mixed meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DXA-scan
Description: Dual energy X-ray Absorptiometry scan of whole-body fat

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DXA-scan
Description: Dual energy X-ray Absorptiometry scan of whole-body fat

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRS
Description: Magnetic resonance spectroscopy of liver fat content

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRS
Description: Magnetic resonance spectroscopy of liver fat content

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Feces collection
Description: 4-day feces collection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Feces collection
Description: 4-day feces collection
Study: NCT06056245

Intervention type: DRUG
Intervention: Post-operative
Description: Installation of IV-PCA of methadone. Program to be used with no background infusion, boluses of 1 mg, and the intervals between boluses of 8 minutes.
Study: NCT05828199

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine Hydrochloride
Description: Comparing between dexmedetomidine versus low dose ketamine infusion in patients undergoing nasal and paranasal sinus surgery as regard, intraoperative hemodynamic stability, blood loss, perioperative opioid requirements, Stress response evaluation through the measurement of serum level of cortisol, IL-6, blood glucose and CRP.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: bolus dose of dexmedetomidine 0.5-1 μg/kg in 100 mL of normal saline over 10 minutes then, continuous infusion dose of dexmedetomidine 0.2 ug/kg/hr
Study: NCT04786587

Intervention type: OTHER
Intervention: self-administered questionnaire
Description: Each pregnant woman completes the self-report during her prenatal consultation and will have a unique blood sampling for dosage of phosphatidylethanol after she returned her self-report to the practitioner and if she is included in the study (informed consent given).~A self-report, including the T-ACE, is the usual prenatal consultation procedure in the three maternities of the study. The specific procedure for the study is to perform a blood test for dosage of phosphatidylethanol in eligible pregnant women after informed consent.
Study: NCT05174910

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Obsidian ASG
Description: Application of an autologous platelet-rich fibrin matrix
Study: NCT05542927

Intervention type: DIAGNOSTIC_TEST
Intervention: urine chloride
Description: Serum chloride, urinary chloride \& serum creatinine will be requested on the first day of admission in Intensive Care Unit (ICU). 2. Serum chloride \& urinary chloride will be requested every 48 hours in ICU with correlation between urinary chloride concentrations, AKI \& mortality. 3. Serum creatinine will be requested every 24 hours in ICU. 4. Monitoring of Urinary Output (U.O.P.) every 24 hours
Study: NCT06005922

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physiotherapy
Description: ultrasound hotpack electrotherapy joint range of motion exercises isometric neck exercises stretching exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiotherapy
Description: ultrasound hotpack electrotherapy joint range of motion exercises isometric neck exercises stretching exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TMJ exercises
Description: tongue relaxation position TMJ isometric strengthening exercises Posture exercises Isometric neck extension in neutral position back extension Strengthening the abdominal muscles Supine dorsal stretch pectoral stretch
Study: NCT05508763

Intervention type: GENETIC
Intervention: Genetic test for 14 pharmacogenes
Description: Genotyping with the Global Diversity Array-8 v1.0 BeadChip with enhanced PGx
Study: NCT06002516

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RELIEF-pathway
Description: The personalized web-based education tool contains information on:~* Information of cause and symptoms of functional dyspepsia, irritable bowel syndrome and uncomplicated symptomatic cholecystolithiasis;~* Symptom checker based on the ROME III and ROME IV criteria;~* Red flags symptoms defined as direct or indirect signs of upper GI hemorrhage.~* Lifestyle adjustments to improve abdominal symptoms and quality of life.~* Information on effect of upper gastrointestinal endoscopy, colonoscopy and laparoscopic cholecystectomy.~After the web-based education tool is completed we will offer an additional visit at the Prevention and Lifestyle clinic, this is optional and not obligatory.
Study: NCT04798716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSC-exosomes delivered intravenously every other day on an escalating dose: (2:4:8)
Description: Escalating dose 2 X 10\^9, 4 X 10\^9, 8 X 10\^9/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSC-exosomes delivered intravenously every other day on an escalating dose (8:4:8)
Description: Escalating dose 8 X 10\^9, 4 X 10\^9, 8 X 10\^9 mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSC-exosomes delivered intravenously every other day (8:8:8)
Description: Dosed 8 X 10\^9, 8 X 10\^9, 8 X 10\^9 mL

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MSC-exosomes delivered intravenously every other day (8:8:8)
Description: Dosed 8 X 10\^9, 8 X 10\^9, 8 X 10\^9 mL
Study: NCT06238206

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Focus group discussion
Description: The participant will be asked to take part in three separate focus group discussions implementing the co-design principle. Following the co-design principle the participants will actively contribute towards the primary outcomes. Open questions will be asked to guide the discussion. Interaction between participants will be encouraged.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Focus group discussion
Description: The participant will be asked to take part in three separate focus group discussions implementing the co-design principle. Following the co-design principle the participants will actively contribute towards the primary outcomes. Open questions will be asked to guide the discussion. Interaction between participants will be encouraged.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Focus group discussion
Description: The participant will be asked to take part in three separate focus group discussions implementing the co-design principle. Following the co-design principle the participants will actively contribute towards the primary outcomes. Open questions will be asked to guide the discussion. Interaction between participants will be encouraged.
Study: NCT04913662

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pressurized Intraperitoneal Aerosol Chemotherapy
Description: Aerosolization of chemotherapic agent for intraperitoneal chemotherapy
Study: NCT04660396

Intervention type: DEVICE
Intervention: BVA-100
Description: The BVA-100 is a software package designed to calculate human blood volume using the method of tracer dilution. It uses tagged serum albumin (a commonly used tag is 131I, resulting in 131I -HSA). Data inputs to the software come from the measured characteristics of subject blood samples (hematocrit and tracer concentration) and tracer calibration standards. The package also calculates the subject expected (or ideal) blood volume from physical parameters. Hyper- or hypovolemia, associated red blood cell volumes, and transudation rate are reported, with statistics showing the quality of the results. The subject blood samples and calibration standards are measured in a gamma counter, whose output is automatically, or manually, input to this calculation program.
Study: NCT05160129

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Selective focal stimulation of ALIC-pathways
Description: DBS will be applied selectively to different electrode contacts/ segments to evaluate clinical, behavioral, and electrocortical responses of specific pathways within the ALIC.
Study: NCT05270798

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: triiodothyronine
Description: Patients in septic shock who meet the diagnostic criteria for euthyroid sick syndrome will be divided into two groups; patients with low T3 levels and patients with low T3 and T4 levels. Both of these groups will be further randomly divided into patients receiving T3 hormone and patients receiving placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triiodothyronine
Description: Patients in septic shock who meet the diagnostic criteria for euthyroid sick syndrome will be divided into two groups; patients with low T3 levels and patients with low T3 and T4 levels. Both of these groups will be further randomly divided into patients receiving T3 hormone and patients receiving placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: triiodothyronine
Description: Patients in septic shock who meet the diagnostic criteria for euthyroid sick syndrome will be divided into two groups; patients with low T3 levels and patients with low T3 and T4 levels. Both of these groups will be further randomly divided into patients receiving T3 hormone and patients receiving placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triiodothyronine
Description: Patients in septic shock who meet the diagnostic criteria for euthyroid sick syndrome will be divided into two groups; patients with low T3 levels and patients with low T3 and T4 levels. Both of these groups will be further randomly divided into patients receiving T3 hormone and patients receiving placebo.
Study: NCT05693792

Intervention type: OTHER
Intervention: Observational
Description: No treatment regimen will be deployed in this follow-up study.
Study: NCT05009251

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder
Description: Mailed letter, short message service (SMS) text, and/or patient portal message

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder
Description: Mailed letter, short message service (SMS) text, and/or patient portal message

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder
Description: Mailed letter, short message service (SMS) text, and/or patient portal message

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder
Description: Mailed letter, short message service (SMS) text, and/or patient portal message

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk reduction
Description: Mailed letter, SMS, and/or patient portal message

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk reduction
Description: Mailed letter, SMS, and/or patient portal message

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk reduction
Description: Mailed letter, SMS, and/or patient portal message

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medical records-based recommendation
Description: Mailed letter, SMS, and/or patient portal message

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medical records-based recommendation
Description: Mailed letter, SMS, and/or patient portal message

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Algorithm-based recommendation
Description: Mailed letter, SMS, and/or patient portal message
Study: NCT05284604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cells (MSCs)
Description: The MSCs are recovered from bone marrows of healthy donors. Each donor is carefully screened for pathogens to assure the product is safe. The MSCs are strictly compliant with FDA standards under Current Good Manufacturing Practice (cGMP) regulations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cells (MSCs)
Description: The MSCs are recovered from bone marrows of healthy donors. Each donor is carefully screened for pathogens to assure the product is safe. The MSCs are strictly compliant with FDA standards under Current Good Manufacturing Practice (cGMP) regulations.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mesenchymal Stem Cells (MSCs)
Description: The MSCs are recovered from bone marrows of healthy donors. Each donor is carefully screened for pathogens to assure the product is safe. The MSCs are strictly compliant with FDA standards under Current Good Manufacturing Practice (cGMP) regulations.
Study: NCT05535452

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Photobiomodulation through LED board
Description: The applications will be performed within 1 hour after radiotherapy, three times a week, by a trained team, consisting of physiotherapists and physiotherapy students, through the sportllux LED plate equipment, medium size, which combines light emitters in two wavelengths: red (660nm) and infrared (850nm).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation through LED board
Description: The applications will be performed within 1 hour after radiotherapy, three times a week, by a trained team, consisting of physiotherapists and physiotherapy students, through the sportllux LED plate equipment, medium size, which combines light emitters in two wavelengths: red (660nm) and infrared (850nm).
Study: NCT05566366

Intervention type: OTHER
Group type: OTHER
Intervention: Qualitative research interview
Description: Qualitative research interview Administration of quantitative scales
Study: NCT04861623

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Orange juice
Description: Orange juice will be purchased commercially.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Orange juice
Description: Orange juice will be purchased commercially.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo juice (Fanta)
Description: Fanta will be purchased commercially.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo juice (Fanta)
Description: Fanta will be purchased commercially.
Study: NCT05072483

Intervention type: DEVICE
Intervention: MRI
Description: Research pulse sequences.

Intervention type: DEVICE
Intervention: MRI
Description: Research pulse sequences.
Study: NCT04442763

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Densah Burs
Description: osseodensification method

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard drills
Description: conventional drilling
Study: NCT05331144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin II Receptor Blockers (ARBs, losartan) and Calcium Channel Blockers (CCB, amlodipine)
Description: Angiotensin II Receptor Blockers (ARBs, losartan) and Calcium Channel Blockers (CCB, amlodipine) will be used to treat high blood pressure. Additional antihypertensive medications may be used if needed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PCP
Description: Participants will follow their PCP's recommendations for BP control.
Study: NCT04488315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone lipid microsphere plus ropivacaine
Description: Local scalp infiltration solution will consist of 30ml miscible liquids containing 8 mg dexamethasone lipid microsphere, 150mg ropivacaine and normal saline.
Study: NCT04897763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-TLX250 PET/CT
Description: Pretherapeutic 89Zr-TLX250 PET/CT
Study: NCT05423171

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive bimanual therapy
Description: 60-hour intensive therapy promoting the use of both hands (ex: bimanual activities, games,...)
Study: NCT05943340

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive exercises
Description: Specific proprioceptive exercises for the shoulder that the patient has to do during the immobilization period.
Study: NCT04488315

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine alone
Description: Local scalp infiltration solution will consist of 30ml miscible liquids containing 150mg ropivacaine and normal saline
Study: NCT06036576

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levothyroxine Pill
Description: all participants will receive levothyroxine treatment of 1.6 micrograms per kg per day early in the morning on empty stomach.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levothyroxine Pill
Description: all participants will receive levothyroxine treatment of 1.6 micrograms per kg per day early in the morning on empty stomach.
Study: NCT06258876

Intervention type: OTHER
Intervention: PrEP in general practice
Description: Prescription and follow-up of PrEP in general practice
Study: NCT06051188

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flow-controlled ventilation
Description: Flow-controlled ventilation (FCV)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flow-controlled ventilation
Description: Flow-controlled ventilation (FCV)
Study: NCT05622279

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous tenotomy + PRP
Description: The patients will receive a percutaneous ultrasound-guided treatment including a needle tenotomy followed by a PRP injection in the plantar fasciitis.
Study: NCT06186037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination drug group of Ezetimibe 10 mg/Rosuvastatin 5 mg
Description: Oral administration once a day, taking it for 3 years
Study: NCT04767984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin Calcium
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy of Colon
Description: Undergo colonoscopy with biopsy

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Biopsy of Colon
Description: Undergo colonoscopy with biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05141604

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Field expansion view
Description: Overlaid small window on HMD to show the part of the scene in the blind field into portions of the participants' remaining, seeing, field of vision
Study: NCT06186037

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mono drug group of Rosuvastatin 20 mg
Description: Oral administration once a day, taking it for 3 years
Study: NCT05503225

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine 0.5 MG
Description: 0.5mg Orally Taken Colchicine
Study: NCT04878913

Intervention type: DRUG
Intervention: C21
Description: C21 was administered in the VP-C21-006 trial

Intervention type: DRUG
Intervention: Placebo
Description: Placebo was administered in the VP-C21-006 trial
Study: NCT04773236

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium bicarbonate 8.4%
Description: mixing the sodium bicarbonate with 2%lidocaine and 1:80.000 epinphrine using mixing pen (onset buffering system)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 2%lidocaine with 1:80.000 epinphrine
Description: injection

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mixing pen (onset buffering system)
Description: Premixing of the two solutions sodium bicarbonate and lidocaine with epinphrine before the local anesthesia adminstration to the patient